Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CLPBY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CLPBY and 80,000+ other tickers.
See exactly how CLPBY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CLPBY and 80,000+ other tickers.
Coloplast A/S, founded in 1954 and headquartered in Humlebæk, Denmark, operates as a global developer and marketer of intimate healthcare products and services. Its extensive reach spans Denmark, the United States, the United Kingdom, France, and numerous other international regions. The company's activities are organized into three primary segments: Chronic Care, Interventional Urology, and Wound & Skin Care. Within Chronic Care, Coloplast provides advanced ostomy solutions, including the SenSura Mio, recognized for its adaptable fit and discretion, alongside other SenSura offerings and…
Coloplast A/S (CLPBY) Q3 2026 Earnings Call Transcript
Medical equipment maker Coloplast expects its Kerecis wound-care business to return to growth from January 2027 after changes to U.S. Medicare payments caused sales in outpatient settings to fall sharply, its finance chief told Reuters on Tuesday.
Coloplast remains a 'Buy,' trading ~20% below intrinsic value despite recent struggles and special charges. Organic growth was 6% in Q2-25/26, but reported results were impacted by a DKK 3 billion Kerecis impairment and currency headwinds. Management guides for 5–6% organic revenue growth and 5% EBIT growth in FY25/26, but targets 7–8% annual organic growth and 20%+ ROIC by FY29/30.
Coloplast is rebased to a 20x P/E with a new price target of 490 DKK, reflecting a more realistic valuation post-premiumization. Recent setbacks—the Kerecis acquisition write-down, product recalls, and regulatory shifts—have driven shares down, but core fundamentals and inelastic product demand remain intact. CLPBY now trades at a historically low sub-18x P/E, offering a 5.76% yield and potential 12–13% annualized growth until 2028E, supporting a buy rating.
Coloplast A/S (CLPBY) Q2 2026 Earnings Call Transcript